Compile Data Set for Download or QSAR
Found 44 Enz. Inhib. hit(s) with all data for assayid = 1 entry = 2982
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387263(N-(2′- acetamido-5′-(5,5- dimethyl-4-o...)copy SMILEScopy InChI
Affinity DataIC50: 100nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387280(N-(2,6- Difluorophenyl)-5-(2- methyl-3-(4-methyl- ...)copy SMILEScopy InChI
Affinity DataIC50: 100nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387261(N-(5′- (5,5-Dimethyl-4-oxo- 4,5-dihydroisoxa...)copy SMILEScopy InChI
Affinity DataIC50: 100nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387264(N-(3′- (5,5-Dimethyl-4-oxo- 4,5-dihydroisoxa...)copy SMILEScopy InChI
Affinity DataIC50: 100nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387265(2,6- Difluoro-N-(2′- methyl-5′-(4-meth...)copy SMILEScopy InChI
Affinity DataIC50: 100nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387266(N-(5′- (4-Ethyl-5-oxo-4,5- dihydro-1,3,4- ...)copy SMILEScopy InChI
Affinity DataIC50: 100nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387267(2,6- Difluoro-N-(2′- methoxy-5′-(4- me...)copy SMILEScopy InChI
Affinity DataIC50: 100nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387268(N-(2′- Chloro-5′-(4-methyl- 5-oxo-4,5-...)copy SMILEScopy InChI
Affinity DataIC50: 100nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387269(2- Chloro-N-(5-(5-(5,5- dimethyl-4-oxo-4,5- dihydr...)copy SMILEScopy InChI
Affinity DataIC50: 100nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387270(2,6- Difluoro-N-(5-(2- methyl-5-(4- methyl-5-oxo-4...)copy SMILEScopy InChI
Affinity DataIC50: 100nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387271(2,6- Difluoro-N-(5-(2- methoxy-5-(4- methyl-5-oxo-...)copy SMILEScopy InChI
Affinity DataIC50: 100nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387272(N-(5-(5- (5,5-dimethyl-4-oxo- 4,5-dihydroisoxazol-...)copy SMILEScopy InChI
Affinity DataIC50: 100nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387273(US10292981, Example 135)copy SMILEScopy InChI
Affinity DataIC50: 100nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387274(N-(2,6- Difluorophenyl)-5-(5- (5,5-dimethyl-4-oxo-...)copy SMILEScopy InChI
Affinity DataIC50: 100nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387276(5-(5- (5,5-Dimethyl-4-oxo- 4,5-dihydroisoxazol- 3-...)copy SMILEScopy InChI
Affinity DataIC50: 100nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387277(N-(2,6- Difluorophenyl)-5-(5- (5,5-dimethyl-4-oxo-...)copy SMILEScopy InChI
Affinity DataIC50: 100nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387278(N-(2,6- Difluorophenyl)-5-(2- ethyl-5-(4-methyl-5-...)copy SMILEScopy InChI
Affinity DataIC50: 100nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387279(5-(2- (Difluoromethoxy)-5- (4-methyl-5-oxo-4,5- di...)copy SMILEScopy InChI
Affinity DataIC50: 100nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387262(N-(5′- (5,5-Dimethyl-4-oxo- 4,5-dihydroisoxa...)copy SMILEScopy InChI
Affinity DataIC50: 100nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387282(N-(6-(5- (5,5-dimethyl-4-oxo- 4,5-dihydroisoxazol-...)copy SMILEScopy InChI
Affinity DataIC50: 550nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387281(N-(5-(5- (5,5-Dimethyl-4-oxo- 4,5-dihydroisoxazol-...)copy SMILEScopy InChI
Affinity DataIC50: 550nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387283(N-(5-(5- (5,5-dimethyl-4-oxo- 4,5-dihydroisoxazol-...)copy SMILEScopy InChI
Affinity DataIC50: 550nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387307(US10292981, Example 138)copy SMILEScopy InChI
Affinity DataIC50: 550nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387306(US10292981, Example 136)copy SMILEScopy InChI
Affinity DataIC50: 550nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387301(N-(2′- (allyloxy)-5′-(5,5- dimethyl-4-...)copy SMILEScopy InChI
Affinity DataIC50: 550nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387284(N-(2′- chloro-5′-(5,5- dimethyl-4-oxo-...)copy SMILEScopy InChI
Affinity DataIC50: 550nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387285(N-(6-(5- (5,5-dimethyl-4-oxo- 4,5-dihydroisoxazol-...)copy SMILEScopy InChI
Affinity DataIC50: 550nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387286(2,6- difluoro-N-(5-(5-(4- methoxy-5,5- dimethyl-4,...)copy SMILEScopy InChI
Affinity DataIC50: 550nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387287(2,6- Difluoro-N-(5′-(4- methoxy-5,5- dimethy...)copy SMILEScopy InChI
Affinity DataIC50: 550nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387288(N-(3′- (5,5-Dimethyl-4-oxo- 4,5-dihydroisoxa...)copy SMILEScopy InChI
Affinity DataIC50: 550nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387289(N-(5-(5- (5,5-dimethyl-4-oxo- 4,5-dihydroisoxazol-...)copy SMILEScopy InChI
Affinity DataIC50: 550nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387290(N-(5- (5,5-Dimethyl-4,5- dihydroisoxazol-3- yl)-2-...)copy SMILEScopy InChI
Affinity DataIC50: 550nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387291(2,6- Difluoro-N-(2′- methyl-5′-(4-oxo-...)copy SMILEScopy InChI
Affinity DataIC50: 550nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387292(N-(5′- (4,4-dimethyl-4,5- dihydrooxazol-2-y...)copy SMILEScopy InChI
Affinity DataIC50: 550nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387293(N-(5-(5- (5,5-Dimethyl-4-oxo- 4,5-dihydroisoxazol-...)copy SMILEScopy InChI
Affinity DataIC50: 550nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387294(US10292981, Example 78)copy SMILEScopy InChI
Affinity DataIC50: 550nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387295(3,5- Dichloro-N-(5-(5-(5,5- dimethyl-4-oxo-4,5- di...)copy SMILEScopy InChI
Affinity DataIC50: 550nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387296(N-(5-(5- (5,5-dimethyl-4-oxo- 4,5-dihydroisoxazol-...)copy SMILEScopy InChI
Affinity DataIC50: 550nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387297(US10292981, Example 121)copy SMILEScopy InChI
Affinity DataIC50: 550nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387299(N-(5-(5- (5,5-dimethyl-4-oxo- 4,5-dihydroisoxazol-...)copy SMILEScopy InChI
Affinity DataIC50: 550nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387310(N-(5-(5- (5,5-Dimethyl-4-oxo- 4,5-dihydroisoxazol-...)copy SMILEScopy InChI
Affinity DataIC50: 1.00E+3nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387309(N-(5-(5- (5,5-dimethyl-4-oxo- 4,5-dihydroisoxazol...)copy SMILEScopy InChI
Affinity DataIC50: 1.00E+3nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387308(N-(2′- (tert-butyl)-5′-(5,5- dimethyl-...)copy SMILEScopy InChI
Affinity DataIC50: 1.00E+3nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent
TargetInterleukin-2(Homo sapiens (Human))
Bristol-Myers Squibb Company

LigandPNGBDBM387312(2,6- Difluoro-N-(5′-(5-(2- hydroxyethyl)-5- ...)copy SMILEScopy InChI
Affinity DataIC50: 1.00E+3nMAssay Description:Jurkat T cells were seeded at a density of 0.5 to 1 million cells per well in RPMI medium. Test compounds from this invention were added to the cells...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2D50Q8BUS Patent